Electra Therapeutics, Inc. (ETRA)
NASDAQ: ETRA · Real-Time Price · USD
7.71
-0.36 (-4.46%)
Nov 4, 2026, 1:58 PM EST - Market open
Company Description
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company.
The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer.
Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders.
Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
Electra Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 18, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Quehuong Dong |
Contact Details
Address: 230 E Grand Avenue, Suite S-100 South San Francisco, California 94080 United States | |
| Phone | (888) 743-2290 |
| Website | electra-therapeutics.com |
Stock Details
| Ticker Symbol | ETRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 2088082 |
| CUSIP Number | 284825106 |
| ISIN Number | US2848251060 |
| Employer ID | 83-2193635 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Quehuong (Kathy) Dong, Pharm.D., M.B.A. | President, Chief Executive Officer, Director |
| Chris Clark, C.F.A. | Chief Financial Officer |
| Kim-Hien Dao, D.O., Ph.D. | Chief Medical Officer |
| Gary S. Koe, Ph.D. | Chief Technical Officer |
| Graham Parry, Ph.D. | Chief Scientific Officer |
| Nancy Stagliano, Ph.D. | Chairperson |
| Matthew Fust, M.B.A. | Director |
| Thomas Geninatti, Ph.D. | Director |
| Carl L. Gordon, Ph.D., C.F.A. | Director |
| Beth Seidenberg, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | SCHEDULE 13G | Filing |
| Sep 28, 2026 | SCHEDULE 13G | Filing |
| Sep 28, 2026 | SCHEDULE 13G | Filing |
| Sep 25, 2026 | SCHEDULE 13D | Filing |
| Sep 21, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 424B4 | Prospectus |
| Sep 18, 2026 | CERT | Certification by an exchange approving securities for listing |
| Sep 18, 2026 | 8-A12B | Registration of securities |
| Sep 17, 2026 | EFFECT | Notice of Effectiveness |